One-year results of combined photodynamic therapy and intravitreal bevacizumab injection for retinal pigment epithelial detachment secondary to age-related macular degeneration

Abstract

Combined PDT and intravitreal bevacizumab may decrease the PED height and stabilize visual acuity at 1 year.

Two-Year Course of Subfoveal Pigment Epithelial Detachment in Eyes with Age-Related Macular Degeneration and Visual Acuity Better than 20/40

“…Thus, we did not use PDT for our cases with relatively good BCVAs, although the intravitreal injections of anti-VEGF drugs alone is still associated with a 0.8–12.9% risk of developing RPE tears [25,26,27]. In the end, the percentage of eyes with a complete resolution of the PED was not high in our study (8–29%) compared to earlier studies which reported more than 50% of the cases to have had a resolution of the PED after PDT alone or in combination with anti-VEGF drugs [28,29]. Based on these studies, our cases might have benefited from more intensive treatment including combined therapy with PDT and anti-VEGF drugs for better resolution of the PED and improvement of vision.…”

Polypoidal Choroidal Vasculopathy

“…30,175,178 Polypoidal choroidal vasculopathy is a chronic, recurrent condition: the need for retreatment with verteporfin PDT or ranibizumab in some patients, especially with longer-term follow-up, is well documented. 30,[55][56][57][58]61,62,66,69,[71][72][73]78,86,89,[91][92][93]126 The recommendations of the panel for monitoring are consistent with the methodology of the majority of the studies retrieved in the literature search on PCV.…”

Ranibizumab Monotherapy in Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment

“…The Verteporfin In Photodynamic Therapy Study (VIP) trial demonstrated that patients with AMD lost less lines of vision when treated with PDT [15], however Axer-Siegel et al [16] found those patients with serous PED may not benefit at all from PDT. More recent studies have reported success in decreasing the number of required anti-VEGF injections and stabilizing vision with a combination of antiVEGF and PDT including for patients with PED [17,18]. There are currently clinical trials in the pipeline investigating some theories that could result in management of this subset of patients.…”